1
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, Utrecht, The Netherlands
2
Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3
Cell and Molecular Biology Group, Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, UK
Mortaz, E., Masjedi, M. R. & Barnes, P. (2011). Identification of Novel Therapeutic Targets in COPD. TANAFFOS (Respiration), 10(2(spiring)), 9–14.
MLA
Mortaz, E., Masjedi, M. R., & Barnes, P. "Identification of Novel Therapeutic Targets in COPD", TANAFFOS (Respiration), 10, 2(spiring), 2011, 9–14.
HARVARD
Mortaz, E., Masjedi, M. R., & Barnes, P. (2011). 'Identification of Novel Therapeutic Targets in COPD', TANAFFOS (Respiration), 10(2(spiring)), pp. 9–14.
CHICAGO
Mortaz, E., Masjedi, M. R. & Barnes, P., "Identification of Novel Therapeutic Targets in COPD." TANAFFOS (Respiration), 10 2(spiring) (2011): 9–14,
VANCOUVER
Mortaz E., Masjedi M. R., Barnes P. Identification of Novel Therapeutic Targets in COPD. TANAFFOS (Respiration). 2011;10(2(spiring)):9–14.
